top of page

Ataxia Treatments: An Evidence Review

  • crothmeyer
  • Mar 24, 2018
  • 2 min read

Updated: Nov 18, 2020

Information sourced from NEJM Journal Watch:

What Is the Evidence for Current Ataxia Treatments?

The American Academy of Neurology guideline subcommittee reviewed the evidence.

Sponsoring Organization: The guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology

Target Population: Patients with cerebellar motor dysfunction and ataxia

Background and Objective

A subcommittee of the American Academy of Neurology reviewed the current evidence on the treatment of cerebellar motor dysfunction and ataxia.

Key Points

  • For episodic ataxia type 2, 4-aminopyridine (15 mg/day) “probably reduces” frequency of ataxia attacks (based on 1 Class I study lasting 3 months).

  • For ataxia of mixed etiology, riluzole “probably improves” ataxia signs (1 Class I study lasting 8 weeks).

  • For Friedreich ataxia or spinocerebellar ataxia (SCA), riluzole “probably improves” ataxia signs (1 Class I study lasting 12 months).

  • For SCA type 3, high-dose valproic acid (1200 mg/day) “possibly improves” ataxia (1 class II study lasting 12 weeks).

  • For spinocerebellar degeneration, thyrotropin-releasing hormone “possibly improves” some ataxia signs (1 Class II study lasting 2 weeks).

  • For Friedreich ataxia, deferiprone “possibly worsens” ataxia signs (1 Class II study lasting 6 months).

  • For degenerative ataxias, an inpatient rehabilitation program “probably improves” ataxia and function (1 Class I study lasting 4 weeks), and transcranial magnetic stimulation “possibly improves” cerebellar motor signs (1 Class II study lasting 21 days).

  • Too few results are available to recommend for or against use of stochastic whole-body vibration therapy (1 Class III study).

COMMENT

This guideline is useful, as many clinicians may have assumed that there are no treatments for cerebellar motor dysfunction and ataxia. Clinicians should pay attention to the type of ataxia and remember that 4-aminopyridine, riluzole, valproic acid, transcranial magnetic stimulation, and rehabilitation all may improve some ataxia symptoms, but improvement generally depends on the ataxia subtype and method of applying the therapy. Lithium and deferiprone may worsen some ataxias. Although the effects of these therapies may be mild, improvement could be meaningful for individual patients with ataxia.

Michael S. Okun, MD reviewing Zesiewicz TA et al. Neurology 2018 Mar.

CITATION(S):

Zesiewicz TA et al. Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018 Mar; 90:464.

NEJM Journal Watch is produced by NEJM Group, a division of the Massachusetts Medical Society. Copyright ©2018 Massachusetts Medical Society. All rights reserved.

The above message comes from NEJM Journal Watch, who is solely responsible for its content

 
 
 

Comments


Featured Monthly Article
Please reload

Recent News

Curt Wood, R.Ph., FASCP

Board Certified Geriatric Pharmacist

Elder Care Pharmacy Consultants take pride in being truly independent. Elder Care Pharmacy Consultants, LLC. has a comprehensive approach to antipsychotic use in order to help ensure nursing homes reach their goals, enhance star quality measures, and maintain federal and state compliance. Our success depends on your satisfaction with the services we provide..

The Consultant Pharmacist's Creed
 
I hold my patients' interest above all others.
 
I take responsibility for my patients' medication-related needs.
 
I ensure my patients' medications are the most appropriate, the most effective available, the safest possible, and are used correctly.
 
I identify, resolve and prevent medication-related problems that may interfere with the goals of therapy.

Address: 17566 Doe Run Rd.

               New London, MO 63459

 

Telephone : (573) 795 - 6351

Fax: (573) 985 - 3076
Email : curt@eldercarepharmacyconsultants.com

Copyright © Elder Care Pharmacy Consultants 2021

  • LinkedIn App Icon
  • Wix Twitter page
"Elder Care Pharmacy Consultants LLC., provides experienced clinical and regulatory pharmacy and consulting services relating to safe and effective medication use to skilled, assisted living, residential care nursing facilities." "Our mission is to provide pharmacy consulting services intended to optimize safe and effective medication use with the goal of helping skilled, assisted living and residential care nursing facilities provide the highest quality of care to achieve the best outcomes and maintain regulatory compliance."
bottom of page